Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences' cell therapy Kite Pharma has ... Xanthopoulos said the deal will "potentially accelerate Shoreline's timeline to the clinic, expand our pipeline opportunities and deliver ...

Detailed price information for Dupont Denemours Inc (DD-N) from The Globe and Mail including charting and trades.

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

Real-time index price for PHLX Housing Index (HGX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The stock's fall snapped a three-day winning streak.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...